This site is intended for a UK healthcare professional audience and NHS relevant decision makers only. General information about KISQALI®▼ (ribociclib) is also provided in the section for members of the public.
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
Reporting side effects: If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of this medicine.
UK | May 2022 | 214780